Clinical Trial Detail

NCT ID NCT02821754
Title A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

biliary tract cancer

hepatocellular carcinoma

Therapies

Durvalumab + Tremelimumab

Age Groups: adult senior

No variant requirements are available.